Mercado Global de Perturbações Genéticas – Tendências do Setor e Previsão para 2030

Análise e dimensão do mercado de doenças genéticas

A incidência de doenças genéticas como a síndrome de Down é causada por uma cópia extra do cromossoma 21 e ocorre em aproximadamente 1 em cada 700 nados-vivos nos Estados Unidos. afro-americanos e a fibrose quística , causada por mutações no gene CFTR, afecta aproximadamente 1 em 2.500 a 3.500 recém-nascidos caucasianos todos os anos.

A Data Bridge Market Research analisa que o mercado das doenças genéticas, que foi de 14.954,67 milhões de dólares em 2022, atingirá os 37.559,50 milhões de dólares até 2030 e deverá crescer um CAGR de 12,2% de 2023 a 2030. " "Doença de Alzheimer" domina o tipo de doença segmento do mercado de Distúrbios Genéticos devido aos crescentes casos da doença na população geriátrica Além dos insights sobre cenários de mercado, como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria do. A pesquisa de mercado da Data Bridge também inclui análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de distúrbios genéticos

Market Definition

Genetic disorders are inherited disorders caused by a change, or mutation in DNA sequence and passed onto the next generation by gene transfer from one generation to the next. They can be life-threatening and progressive, with each disease carrying different symptoms and even very rare and complicated to treat and requiring specialized treatments or therapeutics.

Global Genetic Disorders Market Dynamics

Drivers

• Increasing Prevalence of Genetic Disorders

The rising prevalence rate of genetic diseases and disorders is one of the primary factors boosting the market's growth. For instance, the growing incidence of diabetes in the family history directly boosts the market growth rate. Furthermore, several other genetic diseases such as Edward syndrome, Down syndrome, and Patau syndrome and an increasing geriatric population base susceptible to chronic diseases will rapidly enhance the market growth. Thus, this factor boosts market growth.

• Higher Technological Advancements in Prenatal Genetic Testing

Increasing product design advancements and quality improvement are major parameters that enhance the market's growth. For instance, Avellino Labs announced the launch of AvaGen, the genetic eye test, in the U.S. in 2021. It is designed to help identify a patient's risk of keratoconus and other corneal dystrophies. These initiatives by major market players are anticipated to boost growth. Thus, this factor boosts market growth.

Opportunities

• Increasing Demand for Cell-Free DNA in Maternal Plasma Tests

The cell-free DNA in maternal plasma tests segment is in high demand and is boosting the market growth. It is increasingly being used in identifying the risk of genetic disorders in prenatal care through numerous genetic analyses. Technological advancements now have extended the range of testing to whole-genome sequencing, and they can detect several additional chromosomal anomalies, such as sex chromosomal abnormalities and microdeletions. Thus, this factor is helping in improving the market growth.

• Government Investments for Healthcare Interoperability

The increase in funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the bleeding disorders treatment market.

Restraints/Challenges

• Limited Treatment Options

Many genetic disorders currently have no cure, and treatment options are limited to managing symptoms and improving quality of life. This can limit treatment options and reduce patient adherence to therapy.

• High Cost of Treatment

Genetic disorder treatment costs can be expensive, particularly for rare genetic disorders. This can limit access to treatment and create financial burdens for patients and healthcare systems.

This genetic disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the genetic disorders market, contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In 2021, Sanofi collaborated with mRNA therapeutics company, Translate Bio, to develop mRNA vaccines and therapies for genetic diseases, including cystic fibrosis.
• In 2021, Amicus announced that their gene therapy, AT-GAA, received Breakthrough Therapy designation from the FDA for the treatment of Pompe disease. The therapy uses a recombinant adeno-associated virus vector to deliver patients a functional copy of the missing gene.

Global Genetic Disorders Market Scope

The genetic disorders market is segmented on the basis of indication and disease type. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• CF
• DMD
• LSD
• PNH

 Disease Type

• Alzheimer's Disease
• Cancer
• Cystic fibrosis
• Sickle Cell Anaemia
• DMD
• Thalassemia
• Huntington's Disease
• Rare Diseases
• Others

Global Genetic Disorders Market Regional Analysis/Insights

The genetic disorders market is analysed and market size insights and trends are provided by country, indication and disease type as referenced above.

The countries covered in the genetic disorders  market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the genetic disorders market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having genetic disorders such as Alzheimer's disease, and cystic fibrosis.

Prevê-se que a Ásia-Pacífico testemunhe um crescimento significativo durante o período de previsão de 2023 a 2030 devido ao aumento das iniciativas governamentais para promover os cuidados de saúde, à crescente sensibilização para a saúde entre as pessoas e à crescente procura de tecnologia médica avançada para doenças raras e genéticas, à grande população e à crescente procura de cuidados de saúde de qualidade na região.

A secção nacional do relatório também fornece fatores individuais que impactam o mercado e alterações na regulamentação nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas, análise das cinco forças de Porter e estudos de caso são alguns indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e as rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Análise do cenário competitivo e da quota de mercado dos distúrbios genéticos

O panorama competitivo do mercado das doenças genéticas fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produtos, largura e amplitude do produto, domínio da aplicação. Os dados fornecidos acima estão apenas relacionados com o foco das empresas relacionado com o mercado das doenças genéticas.

Alguns dos principais players que operam no mercado das doenças genéticas são:

• Amicus Therapeutics, Inc.
• Alexion Pharmaceuticals, Inc.
• Sanofi (França)
• Takeda Pharmaceutical Company Limited (Japão)
• Vertex Pharmaceuticals Incorporated EUA)
• F. Hoffmann-La Roche Ltd (Suíça)
• Abbott (EUA)
• Amgen Inc.
• Grupo ELITech (França)
• GW Pharmaceuticals plc. (REINO UNIDO)
• (EUA)
• PerkinElmer Inc (EUA)
• AutoGenómica (EUA)
• (EUA)
• BioMarin (EUA)
• Sarepta Therapeutics (EUA)

SKU-50091